CYTR Stock News 3.41 05/13/2014 16:56:04 Cytrx Corp (CYTR)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytrx Corp (CYTR) 3.41 $CYTR

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against CytRx Corporation and Certain Officers - CYTR
PR Newswire - Fri May 09, 5:15PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company" (NASDAQ: CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRX between November 22, 2013 and March 13, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline -- CYTR
GlobeNewswire - Thu May 08, 10:45AM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company" (Nasdaq:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the "Class Period" .

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company" (Nasdaq:CYTR) common stock between November 22, 2013 and March 13, 2014.

Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline in CytRx Securities Fraud Class Action
PR Newswire - Tue May 06, 11:26AM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company" and the May 13, 2014 deadline to file for lead plaintiff. Investors who have suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing CytRx@hbsslaw.com, calling 510-725-3000 or visiting http://hb-securities.com/investigations/CytRx.

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of CytRx Corporation ("CytRx" or the "Company" (NASDAQ:CYTR) that all purchasers of CytRx securities between November 20, 2013 and March 13, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

CytRx Reports Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma
Business Wire - Mon May 05, 5:00AM CDT
--Median Overall Survival Data Support the Ongoing Clinical Development of Aldoxorubicin in Soft Tissue Sarcoma

Pre-Market Review on Top Gainers -- Research on SouFun Holdings, CytRx, Iridium Communications, and Qihoo 360 Technology
PR Newswire - Fri May 02, 7:12AM CDT
The US markets finished on a mixed note on Thursday, May 01, 2014, with the NASDAQ Composite closing at 4,127.45, up 0.31%, the Dow Jones Industrial Average ending the session at 16,558.87, down 0.13% and the S&P 500 finishing 0.01% lower at 1,883.68. During the trading session, five out of ten sectors finished on a positive note. A number of stocks saw large movements, including SouFun Holdings Ltd (NYSE: SFUN), CytRx Corp. (NASDAQ: CYTR), Iridium Communications Inc. (NASDAQ: IRDM) and Qihoo 360 Technology Co. Ltd (NYSE: QIHU). Free technical research on SFUN, CYTR, IRDM and QIHU can be downloaded upon signing up at:

CYTRX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CytRx Corporation - CYTR
GlobeNewswire - Thu May 01, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 13, 2014 to file lead plaintiff applications in a securities class action lawsuit against CytRx Corporation (Nasdaq:CYTR), if they purchased the Company's securities during the period between November 22, 2013 and March 13, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the Central District of California.

Stock to Watch: CytRx Up 16.3% (CYTR)
Comtex SmarTrend(R) - Thu May 01, 10:41AM CDT
CytRx (NASDAQ:CYTR) is one of today's best performing low-priced stocks, up 16.3% to $3.57 on 1.1x average daily volume. CytRx has traded 2.4 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has outperformed the Dow (16.3% to the Dow's -0.0%) and outperformed the S&P 500 (16.3% to the S&P's 0.1%) during today's trading.

CytRx Reports 2014 First Quarter Financial Results
Business Wire - Thu May 01, 5:01AM CDT
--Global Phase 2b Clinical Trial of Aldoxorubicin Selected for ASCO 2014 Oral Presentation

CytRx to Present Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data in Second-Line Soft Tissue Sarcoma at Upcoming Research and Development Day
Business Wire - Mon Apr 28, 5:01AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma. The trial was conducted at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial's principal investigator, Dr. Sant Chawla, will present the data at CytRx's Research and Development Day which is taking place on Friday, May 2, from 8:30 - 11:30 am EDT at the Harvard Club in New York City.

EQUITY ALERT: Rosen Law Firm Reminds CytRx Corporation Investors of Important May 14, 2014 Deadline in the Class Action Filed by the Firm -- CYTR
GlobeNewswire - Sat Apr 26, 8:51PM CDT
The Rosen Law Firm reminds all purchasers of the common stock of CytRx Corporation (Nasdaq:CYTR) between November 22, 2013, and March 13, 2014, including the CYTR's public offering completed on or before February 5, 2014, of the important May 14, 2014 lead plaintiff deadline.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CytRx Corporation of Class Action Lawsuit and Upcoming Deadline -- CYTR
GlobeNewswire - Fri Apr 25, 3:49PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against CytRx Corporation ("CytRx" or the "Company" (Nasdaq:CYTR) and certain of its officers. The class action, filed in United States District Court, Central District of California and docketed under 14-cv-02689, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of CytRx between November 22, 2013 and March 13, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

CytRx Announces Global Phase 2b Trial of Aldoxorubicin in Soft Tissue Sarcomas Selected for Oral Presentation at the 2014 ASCO Annual Meeting
Business Wire - Thu Apr 24, 6:01AM CDT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin, its lead product candidate, versus doxorubicin in patients with advanced soft tissue sarcomas (STS) has been selected for oral presentation at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 - June 3 in Chicago.

Lieff Cabraser Reminds CytRx Corporation Investors of Upcoming Deadline in Class Action Litigation - CYTR
Business Wire - Wed Apr 23, 8:01AM CDT
Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 14, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired the securities of CytRx Corporation ("CytRx" or the "Company" (NasdaqCM:CYTR) between November 30, 2013 and March 13, 2014, inclusive (the "Class Period" .

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in CytRx Corporation to Contact Brower Piven Before the May 13, 2014 Lead Plaintiff Deadline
Business Wire - Tue Apr 15, 9:00PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation ("CytRx" or the "Company" (NasdaqCM: CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the "Class Period" .

Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of the May 13, 2014 deadline to file for lead plaintiff in the securities fraud class action against CytRx Corporation (Nasdaq:CYTR) ("CytRx" or "the Company" . Investors who have suffered financial losses can contact Gregory Stone at gstone@whafh.com or (212) 545-4774.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against CytRx Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of CytRx Corporation ("CytRx" or the "Company" (NASDAQ:CYTR) between November 20, 2013 and March 13, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 79

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 24

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 73

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 88

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 70

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 158

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 110

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

BriteCap Financial Achieves Major Funding Milestone

Updated Category News Views 124

BriteCap Financial Achieves Major Funding Milestone BriteCap Financial, a leading small business funding platform, has proudly announced that it has surpassed $1 billion in total originations since its inception. This impressive milestone was achieved in late 2025, highlighting a year of remarkable growth and success for the company. Record Growth in 2025 The achievement...

Continue Reading
Aker Horizons ASA's Upcoming Virtual Annual Meeting Details

Updated Category News Views 261

Aker Horizons ASA Announces Details of Virtual Annual Meeting Aker Horizons ASA, a key player in green energy solutions, has scheduled its annual general meeting to take place online. This digital event will allow shareholders to engage and participate from any location, enhancing accessibility for all stakeholders. Details on the Virtual Meeting The annual general...

Continue Reading
Integrated Analytical Solutions Opens New Cannabis Lab Facility

Updated Category News Views 165

Integrated Analytical Solutions Launches a New Cannabis Testing Facility Integrated Analytical Solutions (IAS), renowned for its analytical testing services, is making strides in the cannabis industry with the grand opening of its state-of-the-art cannabis testing laboratory. This facility is a significant addition to services aimed at promoting safety, quality, and...

Continue Reading
Trip.com Group Files 2024 Annual Report with SEC Insights

Updated Category News Views 1309

Trip.com Group Limited Files Annual Report on Form 20-F Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) has announced the submission of its annual report on Form 20-F. This report includes the company's audited financial statements covering the three years leading up to December 31, 2024, presented to the Securities and Exchange Commission. The filing was made recently...

Continue Reading
Revolutionizing Pediatric Healthcare: Office Practicum's Portal

Updated Category News Views 254

Transforming Pediatric Healthcare with an Innovative Portal Office Practicum is leading the charge in pediatric care by introducing a state-of-the-art Patient Portal, created in partnership with BridgeInteract. This comprehensive tool has been tailored specifically for pediatric practices, presenting a modern and user-friendly platform that serves both families and...

Continue Reading